Brainspark takes football stake 19/03/2010
As foreshadowed in the latest Growth Company Investor, investment minnow Brainspark is buying into Italian football club AC Ancona.
Biotech plans to focus on animal vaccines such as for herpes in fish.
Bombed-out anti-viral treatment developer Henderson Morley plans to focus on animal vaccines as it taps the market.
The Birmingham-based biotech company is offering shares at a virtual all-time low of 0.25p both to new investors and existing shareholders, adding for the latter a sweetener of one free share with every ten they buy in the issue. AIM-quoted Henderson’s executive chairman Andrew Knight and fellow directors have underwritten enough new shares to ensure the company collects a minimum £250,000.
Henderson, which lost £548,000 in the six months to last October, originally floated on AIM eight years ago to develop its patented Ionic Contra Viral Therapy (ICVT) as a treatment for herpes, warts, verrucae and kindred human ailments. Knight grumbles that three companies to which ICVT was licenced failed to do much with it and says the company is now talking to ‘several parties’ about selling ICVT for human applications and
concentrating on vaccines for animals, particularly carp and other fish and domestic cats and dogs, since pet owners are considered less likely to haggle over price than farmers.
Knight says this strategy should make the company ‘more focused’, but concedes that biotechnology is a ‘slow burning fuse’. At 0.3p, against 2001’s 4p float price and a 2006 high of 5.78p, the shares remain speculative.
£7,277 That’s what you would have in your portfolio if you had invested £6,000 into the six Company Watch recommendations in our April 2009 issue.
Advertisement
Growth Company Investor, in association with the London Stock Exchange, presents the most wide-ranging and detailed examination of the AIM market: AIM in Review 2010. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The report reveals the top-earning chief executives and remuneration levels at AIM's most profitable and fastest-growing companies. It also examines constituent parts, including basic salary, bonus, pensions, benefits and share-based payments. To order click here.
Free access to the latest AIM stock recommendations and news from the award-winning Growth Company Investor team. Receive our tips on what stocks to buy direct to your inbox every Tuesday and Friday. Find out more today.
Cautious? Positive? Adventurous? Choose between three levels of risk for a fund of funds from Sharefunds, our sister company. Click here for more information.
The brand new, fully updated AIM Guide 2009/2010 is now available to purchase. AIM Guide is the only fully comprehensive guide to AIM and is regarded as 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today and benefit from a £10 discount!
This report's principal aim is to provide business owners seeking funding with information about the amount of funds that VCTs have to invest. Click here for more information.
Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy the Cash Shells 2009 Research Report today or email Halid Delkic to obtain a free two-page abstract.
Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.
Advertisement
As foreshadowed in the latest Growth Company Investor, investment minnow Brainspark is buying into Italian football club AC Ancona.
Gold producer Avocet Mining hopes its Wega acquisition will take 2010 group output to 200,000 oz after a flat nine months.
AIM shell China Evoline is understood to be contemplating the injection of some Chinese mining assets.